Zynerba Pharmaceuticals (ZYNE) News and press releases

Marijuana Stock Movers For May 18, 2022

18 May 22

Cannabis, Markets, Movers

GAINERS: Item 9 Labs (OTC:INLB) shares closed up 21.21% at $1.00

Cannabis Stock Gainers And Losers From May 17, 2022

17 May 22

Cannabis, Markets, Movers

GAINERS: cbdMD (AMEX:YCBD) shares closed up 11.63% at $0.76

Cannabis Stock Gainers And Losers From May 16, 2022

16 May 22

Cannabis, Markets, Movers

GAINERS: Sundial Growers (NASDAQ:SNDL) shares closed up 21.09% at $0.47

Zynerba Pharmaceuticals R&D Expenses Reach $5.1M For Q1 2022, Here Are The Details

16 May 22

Cannabis, Earnings, News, Penny Stocks, Markets

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million.

Recap: Zynerba Pharmaceuticals Q1 Earnings

16 May 22

Earnings, News

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Zynerba Pharmaceuticals Q1 EPS $(0.21) Down From $(0.20) YoY

16 May 22

Earnings, News

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported quarterly losses of $(0.21) per share. This is a 5 percent decrease over losses of $(0.20) per share from the same period last year.

Cannabis Stock Movers For May 11, 2022

11 May 22

Cannabis, Markets, Movers

GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 28.38% at $0.02

Zynerba Pharmaceuticals Presents Long-Term Safety And Efficacy Data Of Zygel In Children And Adolescents With Fragile X Syndrome At The International Society For Autism Research Annual Meeting

11 May 22

News, FDA

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting an oral podium

Stocks That Hit 52-Week Lows On Wednesday

11 May 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Wednesday, 807 companies reached new 52-week lows.

Cannabis Stock Gainers And Losers From May 10, 2022

10 May 22

Cannabis, Markets, Movers

GAINERS: Cara Therapeutics (NASDAQ:CARA) shares closed up 23.76% at $9.22

Marijuana Stock Movers For May 9, 2022

9 May 22

Cannabis, Markets, Movers

GAINERS: Item 9 Labs (OTC:INLB) shares closed up 9.00% at $1.09

Cannabis Stock Movers For May 6, 2022

6 May 22

Cannabis, Markets, Movers

GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 13.33% at $0.02

Stocks That Hit 52-Week Lows On Friday

6 May 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Friday, 1043 companies hit new 52-week lows.

Cannabis Stock Movers For May 5, 2022

5 May 22

Cannabis, Markets, Movers

GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 8.62% at $0.01

Bearish Sentiment Across The Cannabis Space - Check Full Movers For May 3, 2022

3 May 22

Cannabis, Markets, Movers

GAINERS: MGC Pharmaceuticals (OTC:MGCLF) shares closed up 5.91% at $0.02

Bullish Sentiment Across The Cannabis Space - Check Full Movers For May 2, 2022

2 May 22

Cannabis, Markets, Movers

GAINERS: GrowGeneration (NASDAQ:GRWG) shares closed up 9.14% at $6.45

12 Health Care Stocks Moving In Friday's After-Market Session

29 Apr 22

Movers

Gainers Ocular Therapeutix (NASDAQ:OCUL) shares moved upwards by 12.3% to $4.01 during Friday's after-market session. The company's market cap stands at $307.7 million.

Stocks That Hit 52-Week Lows On Thursday

28 Apr 22

News, Options, Intraday Update, Markets

During Thursday, 849 stocks hit new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

27 Apr 22

News, Options, Intraday Update, Markets, Movers, Trading Ideas

Wednesday's session saw 784 companies set new 52-week lows.

Marijuana Stock Movers For April 26, 2022

26 Apr 22

Cannabis, Markets, Movers

GAINERS: LOSERS: Leviathan Natural Prods (OTC:LVCNF) shares closed down 13.22% at $0.66

Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

17 May 22

News, Press Releases

DEVON, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

11 May 22

Health Care, Press Releases

– Data support the long-term safety and effectiveness of Zygel – – Greatest improvements seen in those with complete methylation of their FMR1 gene – DEVON, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Zynerba

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

9 May 22

News, Health Care, Press Releases, General

DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

1 Mar 22

Earnings, Press Releases

– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) – – Continued enrollment in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with FXS; topline

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome

28 Feb 22

Health Care, Press Releases

DEVON, Pa., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric